Product name | Saxagliptin |
CAS No. | 361442-04-8 |
Molecular Formula | C18H25N3O2 |
Molecular Weight | 315.415 |
Quality Standard | 98% up by HPLC |
Appearance | White powder |
ITEMS | SPECIFICATION | RESULT |
Appearance | White powder | Complies |
Odor | Characteristic | Complies |
Assay | ≥ 98% | 99.22% |
Sieve analysis | 100% pass 80 mesh | Complies |
Heavy metals | < 10 ppm | Complies |
As | < 0.1ppm | 0.05 ppm |
Pb | < 0.1ppm | 0.05 ppm |
Cd | < 0.1ppm | 0.05 ppm |
Residual solvents | < 100 ppm | Complies |
Residual pesticide | Negative | Complies |
Total plate count | < 1000 cfu/g | Complies |
Yeast & Mold | < 100 cfu/g | Complies |
E. Coli | Negative | Complies |
Salmonella | Negative | Complies |
|
|
|
Conclusion | The sample complies with the above specification |
Saxagliptin is a highly potent dipeptidyl peptidase-4 (Dipeptidyl Peptidase 4, DPP-4) inhibitor. By selectively inhibiting DPP-4, it can increase endogenous glucagon-like peptide-1 ( Glucagon-like Peptide-1, GLP-1) and glucose-dependent insulinotropic peptide (Glucose-dependent Insulinotropic Peptide, GIP) levels, thereby regulating blood sugar.
Saxagliptin alone can effectively control blood sugar. Combination therapy with metformin or sulfonylurea can control blood sugar earlier and more effectively, improve the rate of patients' blood sugar compliance, and is safe and well tolerated. The HbA1c-lowering effect of saxagliptin was consistent across age, sex, ethnicity, body mass index (BMI), geographic distribution, and duration of diabetes, and was applicable to most patients with type II diabetes.
